Ehijele Olumese

Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.

Cooley advised SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough and other conditions, on its $100 million Series C financing.

Cooley advised Rubicon Technology Partners – a Boulder, Colorado-based private equity firm focused exclusively on investing in and growing software companies – on its majority strategic investment in Vimly Benefit Solutions, a leader in the benefits administration space.

Cooley advised CallTower, an international leader in delivering cloud-based, enterprise-class communications, contact center and collaboration solutions, on its investment from BV Investment Partners.

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.